Dados B3 › PFRM3
PFRM3 (Profarma Distrib Prod): has profit grown?
PFRM3 (Profarma Distrib Prod): in 2025, net income attributable to controlling shareholders was R$ 118.9 million, up 4% versus 2024 (a profit of R$ 114.6 million); five years earlier (2020), a profit of R$ 52.3 million.
| Year | Profit (loss) | Change |
|---|---|---|
| 2025 | R$ 118.9 million | up 4% |
| 2024 | R$ 114.6 million | up 63% |
| 2023 | R$ 70.4 million | down 13% |
| 2022 | R$ 80.9 million | up 3% |
| 2021 | R$ 78.2 million | up 49% |
| 2020 | R$ 52.3 million | up 337% |
| 2019 | R$ 12.0 million | a turn from loss to profit |
| 2018 | -R$ 9.7 million | a loss in both years |
| 2017 | -R$ 112.7 million | a loss in both years |
| 2016 | -R$ 49.0 million | — |
Annual statements (DFP). Profit attributable to controlling shareholders when the company reports it; otherwise total net income. Fact with its source; not investment advice.
Check it yourself
- Open data, no key needed for WEGE3 and with a free key for any company:
https://dadosb3.com/empresas/PFRM3/fatos - Every annual figure comes from the DFP filed with the CVM (dados.cvm.gov.br); dividends come from B3.
- The company page shows the account each number came from: PFRM3.
Dividends · Debt · Full page · How much it returned · plain text for AI
Numbers on this page are live. Data version 2026-10-01-cfo-metodo-direto · page generated 2026-10-17 16:11 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.
Numbers on this page are live. Data version 2026-10-01-cfo-metodo-direto · page generated 2026-10-17 16:11 UTC. If this does not match /saude, you are reading a cached copy.